Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Betta Pharmaceuticals Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Histologically confirmed primary non small cell lung cancer (NSCLC), predominantly non squamous histology (including adenocarcinoma or mixed carcinoma with a major adenocarcinoma component)
2\. Pathologically confirmed stage IA2 high risk to IB NSCLC following complete surgical resection (R0) of primary lung cancer. Disease staging follows the 8th edition of the AJCC/UICC lung cancer staging system.
3\. Post surgical tumour tissue specimens test positive for EGFR sensitizing mutations using an approved assay
4\. Patients in the control group received postoperative observation without any anti tumour therapy prior to disease recurrence or metastasis.
You may not be if
1\. A history of other malignancies within 5 years prior to lung cancer surgery, with the exception of curatively treated malignancies.
2.Prior receipt of systemic anti-tumor therapy for NSCLC within 6 months before lung cancer surgery or before disease recurrence and metastasis.
Clareo Health | Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer
